Page 4 - Pfizer Internal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women s Health
[December 28, 2020]
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women s Health
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™
 (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist ....

United States , Albert Liao , Andy Schmeltz , Nick Lagunowich , Bryan Crowe , Steve Danehy , Lynn Seely , Chuck Triano , Myovant Sciences , Women Health , Drug Administration , Myovant Sciences Conference Call , Exchange Commission , Myovant Sciences Contacts , Pfizer Inc , Myovant Sciences Forward Looking Statement , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Pfizer Announce Collaboration , Commercialize Relugolix , Chief Executive Officer , Global President , Pfizer Internal , New Drug Application , Investor Relations ,